Medical Oncology Department, Barretos Cancer Hospital, São Paulo, Brazil.
Expert Opin Investig Drugs. 2012 Mar;21(3):281-95. doi: 10.1517/13543784.2012.651455. Epub 2012 Jan 12.
Molecularly targeted therapy, with the potential for increased selectivity and fewer adverse effects, hold promise in the treatment of HNSCC.
Targeted agents for HNSCC expected to improve the effectiveness of current therapy including HER family, Src-family kinase, cell cycle, MET, AKT, HDAC, PARP, COX inhibitors and antiangiogenesis.
Epidermal growth factor receptor inhibitors are established in HNSCC and the need now is to find biomarkers for sensitivity to better select patients. Moreover, other pathway inhibitors hold significant promise and are being tested in clinical trials. Angiogenesis inhibition is likely to yield only modest efficacy alone but may augment existing standards. Lastly, one clinical arena where targeted therapies may find secure purchase is in the adjuvant or prevention setting where minimal or preneoplastic disease can be affected by inhibition of a single or few targets.
分子靶向治疗具有增加选择性和减少不良反应的潜力，有望改善头颈部鳞状细胞癌（HNSCC）的治疗效果。
预计针对 HNSCC 的靶向药物将提高当前治疗的效果，包括 HER 家族、Src 家族激酶、细胞周期、MET、AKT、HDAC、PARP、COX 抑制剂和抗血管生成。
表皮生长因子受体抑制剂已在 HNSCC 中得到确立，现在的需求是找到对治疗敏感的生物标志物，以便更好地选择患者。此外，其他途径抑制剂具有很大的应用前景，并正在临床试验中进行测试。抗血管生成抑制单独使用可能疗效有限，但可能增强现有标准。最后，靶向治疗可能有把握应用的一个临床领域是辅助治疗或预防，在这些领域中，通过抑制单个或少数靶点，可以影响到最小或癌前病变疾病。
